Michael J. Overman

Oct 11, 2024 | digitalcommons.library.tmc.edu | Timothy E. Newhook |Michael J. Overman |Yun Shin Chun |Arvind Dasari

OBJECTIVE: To evaluate the association of perioperative ctDNA dynamics on outcomes after hepatectomy for CLM. SUMMARY BACKGROUND DATA: Prognostication is imprecise for patients undergoing hepatectomy for CLM, and ctDNA is a promising biomarker. However, clinical implications of perioperative ctDNA dynamics are not well established.

Jun 20, 2024 | hmpgloballearningnetwork.com | Michael J. Overman

Conference Coverage At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, MD Anderson Cancer Center, Houston, Texas, explores whether or not there is a role for immune therapy right now in the treatment of patients with proficient mismatch repair colorectal cancer. Transcript: I'm Michael Overman, a GI medical oncologist at MD Anderson Cancer Center, and I'm happy to be here talking to you from the 2024 New York Great Debates.

May 24, 2024 | hmpgloballearningnetwork.com | Michael J. Overman

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, MD Anderson Cancer Center, Houston, Texas, discussed advantages associated with use of doublet immunotherapy among patients with MSI-high colorectal cancer. Transcript: Hello, I'm Michael Overman, MD Anderson Cancer Center GI medical oncologist, and I'm here at the 2024 New York Great Debates. We had a discussion today related to immune therapy for MSI-high colorectal cancer.

Apr 11, 2024 | brnw.ch | Michael J. Overman

Michael J. Overman, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, chair, Division of Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center; associate vice president, Research, MD Anderson Cancer Network, discusses future research directions in gastrointestinal (GI) cancers.

Apr 11, 2024 | onclive.com | Michael J. Overman

Michael J. Overman, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, chair, Division of Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center; associate vice president, Research, MD Anderson Cancer Network, discusses future research directions in gastrointestinal (GI) cancers.